Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Monday, November 11, 2024
In the global, double-blind, phase II PERLA trial, chemotherapy in combination with the PD-1 inhibitor dostarlimab-gxly vs pembrolizumab was found to confer numerical improvements in progression-free survival, overall response rates, and overall survival in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). Based on the updated overall survival analysis, which was presented by Solange Peters, MD, PhD, of Lausanne University, Switzerland, and colleagues at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (Abstract 711), the combination continued to show “strong” clinical efficacy with no new safety signals.
“In addition, the previously observed numerical trend in overall survival favoring dostarlimab plus chemotherapy vs pembrolizumab plus chemotherapy was maintained,” the investigators commented.
Systemic therapy–naive patients with no actionable genomic alterations, documented PD-L1 status, and an Eastern Cooperative Oncology Group performance status score of 0 or 1 were enrolled. They were randomly assigned in a 1:1 ratio to receive chemotherapy (pemetrexed at 500 mg/m2 plus carboplatin at AUC of 5 mg/mL/min or cisplatin at 75 mg/m2, followed by pemetrexed) plus either 500 mg of dostarlimab (n = 121) or 200 mg of pembrolizumab (n = 122). The investigators previously identified overall survival as a secondary endpoint.
Overall survival maturity at the time of data cutoff was 67%. The median durations of overall survival were 20.2 and 15.9 months with dostarlimab and pembrolizumab (hazard ratio = 0.74), respectively, with median follow-ups of 31.1 and 31.9 months.
Disclosure: No information regarding conflicts of interest was provided.
JNCCN Spotlights
Resources
For your Patients
